Immuno-Biological Laboratories Co., Ltd.

TSE:4570 Stock Report

Market Cap: JP¥4.5b

Immuno-Biological Laboratories Past Earnings Performance

Past criteria checks 3/6

Immuno-Biological Laboratories has been growing earnings at an average annual rate of 45.4%, while the Life Sciences industry saw earnings growing at 24.8% annually. Revenues have been growing at an average rate of 9.4% per year. Immuno-Biological Laboratories's return on equity is 17.3%, and it has net margins of 25.8%.

Key information

45.4%

Earnings growth rate

46.3%

EPS growth rate

Life Sciences Industry Growth32.0%
Revenue growth rate9.4%
Return on equity17.3%
Net Margin25.8%
Next Earnings Update10 Feb 2025

Recent past performance updates

There May Be Underlying Issues With The Quality Of Immuno-Biological Laboratories' (TSE:4570) Earnings

Nov 20
There May Be Underlying Issues With The Quality Of Immuno-Biological Laboratories' (TSE:4570) Earnings

Recent updates

There May Be Underlying Issues With The Quality Of Immuno-Biological Laboratories' (TSE:4570) Earnings

Nov 20
There May Be Underlying Issues With The Quality Of Immuno-Biological Laboratories' (TSE:4570) Earnings

Immuno-Biological Laboratories (TSE:4570) Seems To Use Debt Rather Sparingly

Aug 03
Immuno-Biological Laboratories (TSE:4570) Seems To Use Debt Rather Sparingly

Investors Shouldn't Be Too Comfortable With Immuno-Biological Laboratories' (TSE:4570) Earnings

May 22
Investors Shouldn't Be Too Comfortable With Immuno-Biological Laboratories' (TSE:4570) Earnings

We Think Immuno-Biological Laboratories (TSE:4570) Can Manage Its Debt With Ease

Feb 29
We Think Immuno-Biological Laboratories (TSE:4570) Can Manage Its Debt With Ease

Is Immuno-Biological Laboratories (TYO:4570) Using Debt In A Risky Way?

Feb 09
Is Immuno-Biological Laboratories (TYO:4570) Using Debt In A Risky Way?

Revenue & Expenses Breakdown

How Immuno-Biological Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4570 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24895231293129
30 Jun 24868226282129
31 Mar 24816186276129
31 Dec 23788-193259179
30 Sep 23866-127262179
30 Jun 23815-220280179
31 Mar 23794-289295179
31 Dec 22753-91271188
30 Sep 22687-195276188
30 Jun 22678-206282188
31 Mar 22647-258310188
31 Dec 21636-258249267
30 Sep 21608-287278267
30 Jun 21611-299300267
31 Mar 21602-318320267
31 Dec 20601-634461318
30 Sep 20593-644478318
30 Jun 20579-673498318
31 Mar 20576-668494318
31 Dec 19592-428472236
30 Sep 19627-376457236
30 Jun 19723-247419236
31 Mar 19781-167397236
31 Dec 18832-60400173
30 Sep 18809-57367173
30 Jun 18797-35355173
31 Mar 18758-52352173
31 Dec 17734-1,9632121,239
30 Sep 17724-2,0232551,239
30 Jun 17733-2,0933111,239
31 Mar 17741-2,0943111,239
31 Dec 16744-195374193
30 Sep 16796-103334193
30 Jun 16733-113303193
31 Mar 16717-31313193
31 Dec 15782-47350159
30 Sep 15715-116380159
30 Jun 15735-76365159
31 Mar 15729-158348159
31 Dec 14665-130337152
30 Sep 14710-56295152
30 Jun 14681-115305152
31 Mar 14670-114291152

Quality Earnings: 4570 has high quality earnings.

Growing Profit Margin: 4570 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4570 has become profitable over the past 5 years, growing earnings by 45.4% per year.

Accelerating Growth: 4570 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4570 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.8%).


Return on Equity

High ROE: 4570's Return on Equity (17.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 20:16
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immuno-Biological Laboratories Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.